Table 1.
Demographic and Clinicopathologic Factors of Patients with High-Grade Soft Tissue Sarcoma
| Variable | All patients (n=1,093) |
Surveyed patients (n=909) |
CXR (n=192) |
CT (n=717) |
p Value (CXR vs CT) |
|---|---|---|---|---|---|
| Demographic | |||||
| Age, y, median (IQR) | 61 (49-72) | 60 (48-71) | 62 (51-76) | 59 (48-71) | 0.02* |
| Sex, n (%) | 0.34 | ||||
| Male | 582 (53) | 480 (53) | 95 (49) | 385 (54) | |
| Female | 511 (47) | 429 (47) | 97 (51) | 332 (46) | |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Race, n (%) | 0.87 | ||||
| White | 818 (75) | 679 (75) | 144 (75) | 535 (75) | |
| Black | 123 (11) | 102 (11) | 22 (11) | 80 (11) | |
| Other | 112 (10) | 100 (11) | 19 (10) | 81 (11) | |
| Missing | 40 (4) | 28 (3) | 7 (4) | 21 (3) | |
| Primary location, n (%) | <0.01* | ||||
| Truncal | 131 (12) | 113 (12) | 18 (9) | 95 (13) | |
| Extremity | 762 (70) | 645 (71) | 157 (82) | 488 (68) | |
| Retroperitoneal | 200 (18) | 151 (17) | 17 (9) | 134 (19) | |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Clinicopathologic factor | |||||
| Tumor size, n (%) | 0.13 | ||||
| < 5 cm | 174 (16) | 137 (15) | 38 (20) | 99 (14) | |
| 5-10 cm | 422 (39) | 366 (40) | 74 (39) | 292 (41) | |
| > 10 cm | 434 (40) | 351 (39) | 70 (36) | 281 (39) | |
| Missing | 63 (5) | 55 (6) | 10 (5) | 45 (6) | |
| Histopathology, n (%) | |||||
| UPS/malignant fibrous histiocytoma | 424 (39) | 355 (39) | 79 (41) | 276 (39) | 0.56 |
| Leiomyosarcoma | 133 (12) | 106 (12) | 18 (9) | 88 (12) | 0.33 |
| Myxofibrosarcoma | 86 (8) | 75 (8) | 23 (12) | 52 (6) | 0.05 |
| Liposarcoma, dedifferentiated | 56 (5) | 40 (4) | 3 (2) | 37 (5) | 0.03* |
| Synovial | 53 (5) | 48 (5) | 11 (6) | 37 (5) | 0.89 |
| Liposarcoma, pleomorphic | 46 (4) | 44 (5) | 10 (5) | 34 (5) | 0.94 |
| Other | 295 (27) | 241 (27) | 48 (25) | 193 (27) | 0.66 |
| Lymph node metastasis, n (%) | 0.69 | ||||
| Negative | 121 (11) | 95 (10) | 9 (5) | 86 (12) | |
| Positive | 25 (2) | 20 (3) | 3 (2) | 17 (2) | |
| Missing | 947 (87) | 794 (87) | 180 (93) | 614 (86) | |
| Lymphovascular | 0.12 | ||||
| invasion, n (%) | |||||
| Negative | 625 (57) | 551 (61) | 130 (68) | 421 (59) | |
| Positive | 54 (5) | 41 (5) | 5 (3) | 36 (5) | |
| Missing | 414 (38) | 317 (35) | 57 (29) | 260 (36) | |
| Final resection status, n (%) | 0.82 | ||||
| R0 | 888 (81) | 755 (83) | 161 (84) | 594 (65) | |
| R1 | 205 (19) | 154 (17) | 31 (16) | 123 (17) | |
| Missing | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| Adjuvant multimodal treatment, n (%) | |||||
| Chemotherapy | 346 (32) | 513 (35) | 65 (34) | 254 (36) | 0.78 |
| Radiation | 582 (53) | 513 (57) | 105 (55) | 410 (57) | 0.55 |
| Mode of lung surveillance, n (%) | |||||
| CXR | 192 (18) | 192 (21) | - | - | |
| CT | 717 (66) | 717 (79) | - | - | |
| First recurrence, n (%) | 455 (43) | 432 (48) | 33 (17) | 399 (56) | <0.01* |
| Local/locoregional | 156 (34) | 149 (34) | 16 (48) | 133 (33) | 0.3 |
| Distant | 249 (55) | 239 (55) | 15 (45) | 224 (56) | 0.3 |
| Both (locoregional + distant) | 48 (11) | 42 (10) | 2 (6) | 40 (10) | 0.3 |
| Lung metastasis† | 234 (79) | 232 (83) | 11 (65) | 221 (83) | <0.01* |
| Median follow-up (months) | 41 | 33 | 48 | 43 | 0.128 |
| Lung metastasis | |||||
| Timing of detection, n (%) | - | - | 0.88 | ||
| < 2 y | - | - | 10 (91) | 188 (85) | |
| 2-5 y | - | - | 1 (9) | 27 (12) | |
| > 5 y | - | - | 0 (0) | 1 (0.4) | |
| Intervention type, n (%) | - | - | 0.77 | ||
| Ablation | - | - | 0 (0) | 1 (0.4) | |
| Radiation | - | - | 1 (9) | 12 (5) | |
| Surgery | - | - | 5 (45) | 94 (43) | |
| Chemotherapy | - | - | 2 (18) | 88 (40) |
*
Significant.
†
Percentage in parentheses calculated with distant metastases (either distant alone or locoregional + distant) as the denominator.
CXR, chest x-ray; IQR, interquartile range; UPS, undifferentiated pleomorphic sarcoma.